Takayasu arteritis (TAK) is a form of large vessel vasculitis resulting in thickening and stenosis of the large-sized arteries, particularly the aorta and its main branches. Ulcerative colitis (UC) is a major complication of TAK, sharing some genetic background and pathogenesis.1 Serum levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α), are potential biomarkers to reflect disease activity of TAK. Thus, IL-6 or TNF-α inhibitors have been used for treating refractory TAK. A randomised controlled trial suggested clinical efficacy and safety of tocilizumab in patients with refractory TAK, although the trial failed to achieve its primary endpoint.2 We here present a patient in whom tofacitinib (TOF), a Janus kinase (JAK) inhibitor, successfully induced a remission of TAK and UC resistant to both TNF-α and IL-6 inhibitors. A 32-year-old Japanese female with a medical history of TAK and UC visited our hospital complaining of chest pain, abdominal …

中文翻译：

---

托法替尼治疗难治性大动脉炎并发溃疡性结肠炎患者成功缓解

Takayasu 动脉炎 (TAK) 是一种大血管炎，导致大动脉增厚和狭窄，尤其是主动脉及其主要分支。溃疡性结肠炎 (UC) 是 TAK 的主要并发症，具有一些遗传背景和发病机制。 1 促炎细胞因子的血清水平，如白细胞介素 6 (IL-6) 和肿瘤坏死因子-α (TNF-α)，是反映 TAK 疾病活动的潜在生物标志物。因此，IL-6 或 TNF-α 抑制剂已被用于治疗难治性 TAK。一项随机对照试验表明托珠单抗在难治性 TAK 患者中的临床疗效和安全性，但该试验未能达到其主要终点。成功地诱导了对 TNF-α 和 IL-6 抑制剂耐药的 TAK 和 UC 的缓解。一位有 TAK 和 UC 病史的 32 岁日本女性来我院就诊，主诉胸痛、腹...